BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Average Rating of “Moderate Buy” by Brokerages

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) have been assigned a consensus rating of “Moderate Buy” from the six analysts that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $14.67.

Several equities analysts have recently issued reports on BCRX shares. StockNews.com raised shares of BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, August 6th. Needham & Company LLC restated a “buy” rating and issued a $14.00 price target on shares of BioCryst Pharmaceuticals in a research report on Tuesday. HC Wainwright reiterated a “buy” rating and set a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, August 6th. JMP Securities raised their price objective on BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the stock a “market outperform” rating in a research note on Tuesday, August 6th. Finally, Barclays boosted their target price on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a research report on Tuesday.

Institutional Trading of BioCryst Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of BCRX. CWM LLC lifted its stake in BioCryst Pharmaceuticals by 200.0% in the 2nd quarter. CWM LLC now owns 5,658 shares of the biotechnology company’s stock worth $35,000 after acquiring an additional 3,772 shares in the last quarter. Signaturefd LLC lifted its position in shares of BioCryst Pharmaceuticals by 560.5% in the second quarter. Signaturefd LLC now owns 6,598 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 5,599 shares in the last quarter. Seven Eight Capital LP acquired a new stake in shares of BioCryst Pharmaceuticals during the first quarter worth approximately $57,000. Mirae Asset Global Investments Co. Ltd. grew its position in BioCryst Pharmaceuticals by 21.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock valued at $57,000 after purchasing an additional 1,322 shares in the last quarter. Finally, Natixis increased its stake in BioCryst Pharmaceuticals by 400.6% in the 1st quarter. Natixis now owns 11,684 shares of the biotechnology company’s stock valued at $59,000 after buying an additional 9,350 shares during the period. Institutional investors and hedge funds own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Stock Performance

Shares of NASDAQ BCRX opened at $7.78 on Friday. BioCryst Pharmaceuticals has a 1 year low of $4.03 and a 1 year high of $8.88. The firm has a market cap of $1.61 billion, a P/E ratio of -12.75 and a beta of 1.89. The stock has a fifty day moving average price of $7.76 and a two-hundred day moving average price of $7.00.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its earnings results on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share for the quarter, meeting the consensus estimate of ($0.07). The firm had revenue of $117.10 million for the quarter, compared to the consensus estimate of $113.99 million. During the same period in the prior year, the business earned ($0.19) EPS. The company’s quarterly revenue was up 35.1% compared to the same quarter last year. On average, research analysts predict that BioCryst Pharmaceuticals will post -0.37 earnings per share for the current fiscal year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.